Correlation Between Synaptogenix and Ascendis Pharma
Can any of the company-specific risk be diversified away by investing in both Synaptogenix and Ascendis Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Synaptogenix and Ascendis Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Synaptogenix and Ascendis Pharma AS, you can compare the effects of market volatilities on Synaptogenix and Ascendis Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Synaptogenix with a short position of Ascendis Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Synaptogenix and Ascendis Pharma.
Diversification Opportunities for Synaptogenix and Ascendis Pharma
0.1 | Correlation Coefficient |
Average diversification
The 3 months correlation between Synaptogenix and Ascendis is 0.1. Overlapping area represents the amount of risk that can be diversified away by holding Synaptogenix and Ascendis Pharma AS in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Ascendis Pharma AS and Synaptogenix is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Synaptogenix are associated (or correlated) with Ascendis Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Ascendis Pharma AS has no effect on the direction of Synaptogenix i.e., Synaptogenix and Ascendis Pharma go up and down completely randomly.
Pair Corralation between Synaptogenix and Ascendis Pharma
Given the investment horizon of 90 days Synaptogenix is expected to generate 2.44 times more return on investment than Ascendis Pharma. However, Synaptogenix is 2.44 times more volatile than Ascendis Pharma AS. It trades about 0.11 of its potential returns per unit of risk. Ascendis Pharma AS is currently generating about 0.14 per unit of risk. If you would invest 285.00 in Synaptogenix on September 4, 2024 and sell it today you would earn a total of 28.00 from holding Synaptogenix or generate 9.82% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Synaptogenix vs. Ascendis Pharma AS
Performance |
| Timeline |
| Synaptogenix |
| Ascendis Pharma AS |
Synaptogenix and Ascendis Pharma Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Synaptogenix and Ascendis Pharma
The main advantage of trading using opposite Synaptogenix and Ascendis Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Synaptogenix position performs unexpectedly, Ascendis Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ascendis Pharma will offset losses from the drop in Ascendis Pharma's long position.| Synaptogenix vs. Annovis Bio | Synaptogenix vs. Cyclo Therapeutics | Synaptogenix vs. Reviva Pharmaceuticals Holdings | Synaptogenix vs. INmune Bio |
| Ascendis Pharma vs. Apellis Pharmaceuticals | Ascendis Pharma vs. BeiGene | Ascendis Pharma vs. Akero Therapeutics | Ascendis Pharma vs. Blueprint Medicines Corp |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Complementary Tools
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |